Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With Dyslipidemia

NCT04823611 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04823611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04823611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and 2 Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of AZD8233 Following a Multiple Subcutaneous Dose Administration in Japanese Participants With Dyslipidemia
Lead sponsor
AstraZeneca
Phase
Phase 1/2
Overall status
Completed
Start date
January 20, 2021
Completion date
September 10, 2022
Enrollment
87 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemia